Enhancing the insulin-like growth factor 1 (IGF-1) signaling pathway reduces HTT toxicity changes associated with increased caspase-6 activation, and IGF-1 treatment has demonstrated therapeutic benefits in HD mouse models [356,359,360,361]. This evidence concerns the gene CASP6 and Huntington disease.